BioRestorative Therapies, Inc. (BRT) reported significant financial challenges in its latest 10-Q filing for the third quarter of 2025, revealing a net loss of $3.0 million for the three months ending September 30, 2025, compared to a loss of $1.1 million during the same period in 2024. For the nine months ended September 30, 2025, the company recorded a net loss of $11.0 million, up from $7.3 million in the prior year. Revenue for the third quarter plummeted to $11,800, a stark decline from $233,600 in the same quarter of 2024, primarily due to a decrease in product sales and a modest increase in royalty revenue.
The company's financial position has deteriorated significantly, with total assets dropping to $5.6 million as of September 30, 2025, down from $12.3 million at the end of 2024. This decline is attributed to a substantial decrease in investments held in marketable securities, which fell from $10.2 million to $3.9 million. Current liabilities remained relatively stable at $3.4 million, while stockholders' equity decreased sharply from $8.5 million to $2.2 million, reflecting the ongoing operational losses and a growing accumulated deficit of $166.7 million.
Operationally, BRT has been focusing on its Disc/Spine Program, particularly the development of its lead product, BRTX-100, which is intended for the treatment of chronic lower back pain. The company has received FDA authorization to commence a Phase 2 clinical trial for this product and has made progress in patient enrollment and site agreements. However, research and development expenses surged to $2.6 million in the third quarter, a 78.5% increase compared to the previous year, driven by costs associated with the clinical trial and recruitment efforts.
In terms of strategic developments, BRT has engaged in financing activities, raising approximately $2.0 million through the sale of common stock under its at-the-market offering agreement. Despite these efforts, the company reported negative cash flows from operations of $8.4 million for the nine months ended September 30, 2025, raising concerns about its liquidity and ability to sustain operations. The company has indicated that it may need to secure additional financing to continue its development plans and has expressed substantial doubt about its ability to continue as a going concern for at least the next twelve months.
Looking ahead, BRT anticipates continued net losses and negative cash flows as it executes its development plans. The company is actively seeking additional funding sources to support its operations and clinical trials, while also exploring potential collaborations to enhance its product offerings. The management remains committed to addressing its financial challenges and improving its operational efficiency in the coming quarters.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. develops cell-based therapeutic products primarily using adult stem cells for regenerative medicine. Its core programs target chronic lower back pain via BRTX-100, an autologous mesenchymal stem cell therapy for disc and spine conditions, and metabolic disorders through the ThermoStem platform using brown adipose-derived stem cells. The company also operates a biocosmeceuticals segment offering cell-based aesthetic products. It focuses on minimally invasive treatments with proprietary technology and clinical-grade manufacturing.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.